{"id":"NCT02291679","sponsor":"Ironwood Pharmaceuticals, Inc.","briefTitle":"Trial of Linaclotide in Patients With Chronic Idiopathic Constipation","officialTitle":"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 ug or 145 ug) Administered Orally for 12 Weeks to Patients With Chronic Idiopathic Constipation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-10","primaryCompletion":"2015-08","completion":"2015-08","firstPosted":"2014-11-14","resultsPosted":"2017-05-19","lastUpdate":"2017-06-15"},"enrollment":1223,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Idiopathic Constipation"],"interventions":[{"type":"DRUG","name":"Linaclotide","otherNames":["Linzess","Constella"]},{"type":"DRUG","name":"Matching Placebo","otherNames":[]}],"arms":[{"label":"72 μg linaclotide","type":"EXPERIMENTAL"},{"label":"145 μg linaclotide","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this trial was to determine the efficacy and safety of linaclotide 72 ug administered once daily to patients with chronic idiopathic constipation (CIC). The primary efficacy parameter is the percentage of participants in each dosing group that meet the protocol definition for complete spontaneous bowel movement (CSBM) Overall Responder.","primaryOutcome":{"measure":"Percentage of 12-Week CSBM Overall Responders","timeFrame":"Week 12","effectByArm":[{"arm":"Placebo","deltaMin":4.7,"sd":null},{"arm":"72 μg Linaclotide","deltaMin":13.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":95,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":401},"commonTop":["Diarrhea"]}}